{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Volume+Control&page=25",
    "query": {
      "intervention": "Volume Control",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 1095,
    "total_pages": 110,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Volume+Control&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Volume+Control&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T03:25:35.347Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01287039",
      "title": "A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Asthma"
      ],
      "interventions": [
        {
          "name": "Reslizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 489,
      "start_date": "2011-04",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2021-11-09",
      "last_synced_at": "2026-10-28T03:25:35.347Z",
      "location_count": 26,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Orange, California + 23 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01287039"
    },
    {
      "nct_id": "NCT01464307",
      "title": "Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Post-stroke Spasticity of the Lower Limb"
      ],
      "interventions": [
        {
          "name": "IncobotulinumtoxinA (400 Units)",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merz Pharmaceuticals GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 290,
      "start_date": "2011-12",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2016-11-07",
      "last_synced_at": "2026-10-28T03:25:35.347Z",
      "location_count": 12,
      "location_summary": "Downey, California • Long Beach, California • Fairfield, Connecticut + 9 more",
      "locations": [
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01464307"
    },
    {
      "nct_id": "NCT03530345",
      "title": "Efficacy and Safety of Intravenous Neridronic Acid in CRPS",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Complex Regional Pain Syndrome (CRPS)"
      ],
      "interventions": [
        {
          "name": "Neridronic acid 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Grünenthal GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2018-05-30",
      "completion_date": "2019-07-31",
      "has_results": true,
      "last_update_posted_date": "2020-08-06",
      "last_synced_at": "2026-10-28T03:25:35.347Z",
      "location_count": 39,
      "location_summary": "Huntsville, Alabama • Mobile, Alabama • Peoria, Arizona + 35 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03530345"
    },
    {
      "nct_id": "NCT07881757",
      "title": "A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Apnea",
        "Sleep Disorders",
        "Overweight and/or Obesity"
      ],
      "interventions": [
        {
          "name": "Berobenatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 258,
      "start_date": "2026-10-19",
      "completion_date": "2028-07-20",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-10-28T03:25:35.347Z",
      "location_count": 2,
      "location_summary": "Bradenton, Florida • Tomball, Texas",
      "locations": [
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Tomball",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07881757"
    },
    {
      "nct_id": "NCT01441271",
      "title": "Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Clostridium Difficile Colitis"
      ],
      "interventions": [
        {
          "name": "Ileal diversion and lavage",
          "type": "PROCEDURE"
        },
        {
          "name": "total abdominal colectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2012-09",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2015-05-01",
      "last_synced_at": "2026-10-28T03:25:35.347Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01441271"
    },
    {
      "nct_id": "NCT00606905",
      "title": "Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Miscarriage, Recurrent",
        "Abortion, Habitual"
      ],
      "interventions": [
        {
          "name": "Gamimune N or Gamunex 10%",
          "type": "BIOLOGICAL"
        },
        {
          "name": "normal saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 82,
      "start_date": "1999-11",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2012-10-08",
      "last_synced_at": "2026-10-28T03:25:35.347Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00606905"
    },
    {
      "nct_id": "NCT04828551",
      "title": "Noninvasive Biomarkers of Metabolic Liver Disease 1.1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis",
        "Nonalcoholic Fatty Liver"
      ],
      "interventions": [
        {
          "name": "Ultrasound based shear wave speed and fat quantification methods",
          "type": "DEVICE"
        },
        {
          "name": "Blood collection",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Physical measurements",
          "type": "OTHER"
        },
        {
          "name": "Clinical history and medication reviews",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2021-03-18",
      "completion_date": "2021-11-20",
      "has_results": true,
      "last_update_posted_date": "2023-07-11",
      "last_synced_at": "2026-10-28T03:25:35.347Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04828551"
    },
    {
      "nct_id": "NCT00044070",
      "title": "A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cerebrovascular Accident"
      ],
      "interventions": [
        {
          "name": "YM872 (zonampanel)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-12",
      "completion_date": "2003-01",
      "has_results": false,
      "last_update_posted_date": "2006-04-03",
      "last_synced_at": "2026-10-28T03:25:35.347Z",
      "location_count": 60,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00044070"
    },
    {
      "nct_id": "NCT03384966",
      "title": "A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stable Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Selatogrel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Viatris Innovation GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 346,
      "start_date": "2018-01-24",
      "completion_date": "2018-09-18",
      "has_results": true,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-10-28T03:25:35.347Z",
      "location_count": 7,
      "location_summary": "Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lutherville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03384966"
    },
    {
      "nct_id": "NCT02415127",
      "title": "Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Friedreich's Ataxia"
      ],
      "interventions": [
        {
          "name": "Interferon γ-1b",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "10 Years to 25 Years"
      },
      "enrollment_count": 92,
      "start_date": "2015-06",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2024-12-19",
      "last_synced_at": "2026-10-28T03:25:35.347Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02415127"
    }
  ]
}